1. Healthcare

  2. •

    Biotechnology
Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc.

KERX
Keryx Biopharmaceuticals, Inc.US flagNASDAQ
3.36
USD
- -
- -
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
TTM
Revenue per Share
0.02
0.01
0.02
0.03
0.5
- -
0.07
- -
0.09
0.12
0.13
0.3
0.53
0.79
Basic EPS, GAAP
-0.78
-1.76
-2.07
-1.18
0.21
-0.34
-0.42
-0.32
-0.58
-1.23
-1.19
-1.52
-1.43
-0.76
Free Cash Flow per Basic Share
-0.78
-1.43
-1.39
-0.87
-0.11
-0.28
-0.34
-0.35
-0.43
-0.91
-1.25
-0.84
-0.83
-0.82
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-3.33
-4.49
-6.38
-7.39
-6.44
-5.79
-5.49
-5.48
-5.42
-6.05
-6.49
-7.89
-8.72
-8.82
Tangible Book Value per Share
2.75
2.86
0.95
-0.1
0.58
0.34
0.41
0.1
0.52
0.77
0.81
-0.11
-0.15
-0.48
Basic Weighted Avg Shares
34
42
44
45
50
59
67
72
81
91
104
106
115
120
Sales/Revenue/Turnover
1
1
1
1
25
- -
5
- -
7
11
14
32
61
94
Operating Margin (%)
-5,089.2
-15,010.67
-9,016.3
-3,978.25
38.97
- -
-574.98
- -
-672.61
-1,027.52
-811.9
-383.84
-167.69
-94.04
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
Net Income, GAAP
-27
-74
-90
-53
10
-20
-28
-23
-47
-112
-123
-161
-163
-91
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-4,685.54
-13,813.48
-8,585.51
-4,121.67
41.62
- -
-562.46
- -
-667.6
-1,030.19
-900.18
-503.69
-269.52
-96.41
Working Capital
84
103
42
9
29
23
30
7
42
69
172
111
96
69
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
91
125
125
147
Total Equity
95
124
44
-1
32
23
31
10
45
73
87
-8
-14
-54
Return on Invested Capital (%)
- -
- -
- -
- -
64.15
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-3.21
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'18
Jun'18
Sep'18
ST Debt
- -
- -
- -
LT Borrowings
125
130
147
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
120
120
120
Market Capitalization
481
450
408

Working Capital

FRC

•

in mil. unless spec.
Mar'18
Jun'18
Sep'18
Total Current Assets
120
126
126
Cash, Cash Equivalents & STI
60
49
41
Accounts Receivable, Net
13
15
15
Inventories
35
49
59
Total Current Liabilities
45
55
57
Payables & Accruals
41
49
51
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-204.6%
74.63%
69.9%
Free Cash Flow
33.22%
42.12%
6.84%
Net Income, GAAP
-14.89%
57.4%
1.46%
Sales/Revenue/Turnover
- -
68.88%
89.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
7
9
6
10
32
2017
12
15
15
19
61
2018
22
26
28
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-0.39
-0.42
-0.39
-0.32
-1.52
2017
-0.21
-0.77
-0.2
-0.26
-1.43
2018
-0.18
-0.18
-0.14
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Company Description

APIChat
Sector
Healthcare
Industry
Biotechnology
Address
IPO Date
Jul 28, 2000
CIK
0001114220
Similar Companies
OmniAb, Inc. (OABI)
Adverum Biotechnologies, Inc. (ADVM)
Acer Therapeutics Inc. (ACER)
Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS)
Fresh2 Group Limited (FRES)
IMV Inc. (IMVIQ)
Business
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of renal disease. Its core products include Auryxia (ferric citrate), an FDA-approved oral absorbable iron-based compound used to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis and to treat iron deficiency anemia in adults with CKD not on dialysis. Auryxia is also marketed in Japan under the brand name Riona through strategic partnerships with Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. The company operates globally with commercial and operational presence in the United States, including offices in Boston and New York, and has additional operations in the UK and Israel. Founded in 1997 and headquartered in Boston, Massachusetts, Keryx's product portfolio targets kidney disease patients with a focus on managing hyperphosphatemia and related complications. In recent years, Keryx underwent a significant strategic change through its merger with Akebia Therapeutics in 2018, forming an expanded entity with a complementary nephrology portfolio, including the late-stage HIF-PHI candidate vadadustat for anemia treatment in CKD. Following the merger, Keryx continues to operate as a wholly-owned subsidiary of Akebia Therapeutics. The company has also engaged in manufacturing and supply agreements, such as its master manufacturing services agreement with Siegfried. Recent developments include regulatory submissions and clinical trials focused on expanding the indications for ferric citrate, enhancing treatment options for non-dialysis dependent CKD patients. Keryx maintains strategic alliances in Japan and with partners for development and marketing in other regions to broaden its market reach and support commercialization efforts.